Viracta Therapeutics announced that the European Commission has granted an orphan drug designation to Viracta’s all-oral combination product candidate, Nana-val for the treatment of diffuse large B-cell lymphoma. The EC previously granted ODD to Nana-val for the treatment of peripheral T-cell lymphoma. In addition, Nana-val was previously granted ODD by the U.S. Food and Drug Administration for the treatment of T-cell lymphoma, post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and Epstein-Barr virus-positive DLBCL, not otherwise specified.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VIRX:
- Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma
- Viracta announces first clinical response in EBV+ solid tumor setting
- Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives
- Viracta reports Phase 1b/2 trial results for Nana-val in EBV+ tumors
- Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress
